amoxicillin-potassium-clavulanate-combination has been researched along with Leukemia--Lymphocytic--Chronic--B-Cell* in 3 studies
3 other study(ies) available for amoxicillin-potassium-clavulanate-combination and Leukemia--Lymphocytic--Chronic--B-Cell
Article | Year |
---|---|
A case of polymorphic dermal angiitis in a B-cell chronic lymphocytic leukemia patient during rituximab therapy.
The aim of the study is to describe a case is of clinical interest as the first known occurrence of skin vasculitis during rituximab treatment. The article describes a case of polymorphic dermal angiitis, a combination of hemorrhagic and ulcerative-necrotic forms against the background of rituximab treatment in a 53-year-old woman suffering from chronic lymphocytic leukemia (b-CLL). During four hours after the 5th intravenous administration of rituximab, the appearance of painful rashes on the skin of both shins of a patient was observed. In the following few days, a progression of the pathological skin process was noted. The treatment with prednisolone in the amount of 50 mg/day, amoxicillin and clavulanic acid in the amount of 1000 mg twice per day and Diflucan in a dosage of 50 mg/day for 15 days was prescribed. In a local therapy, wet-drying bandages with antiseptic solutions, combined topic glucocorticosteroid preparations, drugs that improve trophic and tissue regeneration were recommended. After discharge, the patient continued to receive prednisolone in the amount of 50 mg/day for 14 days with a slow decrease in the dosage of the drug until the withdrawal under the supervision of a dermatologist. The described experience of how combined forms of polymorphic dermal angiitis are developing can be considered a result of toxic drug response to rituximab. Topics: Adrenal Cortex Hormones; Amoxicillin-Potassium Clavulanate Combination; Antineoplastic Agents, Immunological; Bandages; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Vasculitis | 2022 |
Laryngeal actinomycosis in an immunocompromised patient.
Actinomycosis of the larynx represents an unusual presentation for a common bacterium comprising the oral and oropharyngeal florae. There are few cases reported in the literature of laryngeal actinomycosis occurring primarily in the immunocompromised population. Here, we present a case in a 74-year-old man that occurred in the setting of neutropenia as a result of chemotherapy. Once the diagnosis was made with biopsy of the larynx, the infection was resolved after a prolonged course of penicillin-based therapy. Topics: Actinomycosis; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Ciprofloxacin; Drug Therapy, Combination; Humans; Immunocompromised Host; Laryngeal Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[Necrotizing subcutaneous infection by Streptococcus agalactiae].
Necrotizing soft tissue infections constitute some of the most potentially threatening infections that may be acquired in the community or in the hospital milieu as they are associated with a high mortality rate. In most cases they are produced by Streptococcus pyogenes. We report a case of a necrotizing soft tissue infection caused by Streptococcus agalactiae (group B beta hemolytic streptococcus) that involved the leg of an elderly man with chronic lymphatic leukemia and diabetes mellitus. The lesions notably improved after initiating intravenous antibiotic treatment with amoxicillin-clavunate and clindamycin. Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Clindamycin; Combined Modality Therapy; Debridement; Diabetes Mellitus, Type 2; Elbow Injuries; Fasciitis, Necrotizing; Humans; Immunocompromised Host; Leg; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Soft Tissue Infections; Streptococcus agalactiae; Wound Infection | 2006 |